

**Virginia Medicaid Preferred Drug List (PDL) Program:
Annual Review of PDL Phase II and Review of New Drugs and Potential New Classes
Pharmacy and Therapeutics Committee Meeting
Monday, April 20, 2009
10:00 a.m., 7th Floor Conference Rooms
DRAFT AGENDA**

**Welcome and Comments from
DMAS' Director**

**Patrick Finnerty,
DMAS Director**

Comments from the Chairperson

**Randy Axelrod, M.D.,
Chairman**

**Acceptance of Minutes From
October 23, 2008 P&T Meeting**

P&T Committee Members

Drug Class Discussions

P&T Committee Members

Review of Potential New Drug Classes

In current categories

- Otic Quinolones- **Antibiotics**
- Topical Antivirals- **Antivirals**
- Intranasal Antihistamines- **Asthma-
Allergy**
- Non-Ergot Dopamine Receptor
Agonists-**Central Nervous system**
- Calcitonins- **Osteoporosis**

Potential New Categories

Immunologic agents

- Self Administered Drugs For RA-
- Multiple Sclerosis Agents
- Immunosuppressant's

Dermatologic

- Combination Benzoyl Peroxide &
Clindamycin
- Topical Retinoids
- Topical Agents For Psoriasis

Review of New Drugs in PDL Phase I

Electrolyte Depleters

- Calcium Acetate 667MG
- Eliphos

Lipotropics – Fibric Acid Derivatives

- Trilipix™

Corticosteroid Nebulizer solutions

- budesonide

Phase II PDL Annual Review

Oral Hypoglycemics

- Second Generation Sulfonylureas
- Alpha-Glucosidase Inhibitors
- Biguanides
- Biguanide Combination
- Meglitinides
- Thiazolidinediones
- Thiazolidinediones-Metformin
Combinations
- Thiazolidinediones-Sulfonylurea
Combinations
- DPP-IV Inhibitors

Protein Pump Inhibitors

- Prilosec susp
- Kapidex

Antibiotics/Anti-infective

- Second Generation Cephalosporins
- Third Generation Cephalosporins
- Second Generation Quinolones -
Systemic
- Third Generation Quinolones -
Systemic
- Macrolides - Adult and Pediatric
- Oral Antifungals for Onychomycosis
- Herpes Antivirals
- Influenza Antivirals
- Ketolides
- Topical Antibiotics

Central Nervous System

- Antihyperkinesia/CNS Stimulants

Osteoporosis

- Bisphosphonates

Leukotriene

- Leukotriene Modifiers
- Leukotriene Formation Inhibitors

Phase II PDL Annual Review (con't)

Analgesics

- Non-Steroidal Anti-Inflammatory Drugs (NSAID) (*now includes Cox-2 Inhibitors*)
- Long Acting Narcotics

Ophthalmics

- Glaucoma Alpha-2 Adrenergic
- Glaucoma Beta-blockers
- Glaucoma Carbonic Anhydrase Inhibitors
- Glaucoma Prostaglandin Analogs
- Ophthalmic Anti-Inflammatory (NSAID)
- Ophthalmic Quinolones
- Ophthalmic Antihistamines
- Ophthalmic Mast Cell Stabilizers

Miscellaneous

- Serotonin Receptor Agonists (Triptans)

Confidential Meeting

Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information

Criteria Discussion of New Drug Classes*

P&T Committee Members

Criteria Discussion of Phase I New Drugs*

P&T Committee Members

Criteria Discussions for PDL Phase II Drug Classes*

P&T Committee Members

Next Meeting – TBD

**Randy Axelrod, M.D.,
Chairman**

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions*

Oral presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on ***only*** the drug classes subject to PDL Phase II annual review, potential new drug classes, and specific new drugs in PDL Phase I classes listed on the Agenda. All presentations must include newly published information (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase II Annual Review – April 2008 to present
- New Drugs in PDL Phase I Drug Classes – April 2007 to present
- Potential New Drug Classes – April 2007 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

If you are interested in providing specific clinical information to the Committee at the meeting, please submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmavirginia.gov by **COB Tuesday, April 1, 2009**.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmavirginia.gov by **COB Tuesday, April 1, 2009**.